ゴールドカップナショナルマッチ

DSpaceデジタルリポジトリシステムは、デジタル研究資料の捕捉・保管・索引化・保存・配布を行います。 http://ginmu.naramed-u.ac.jp:80/dspace 2024-05-12T09:25:40Z 2024-05-12T09:25:40Z Ikeda, Hiroki Miyao, Shintaro Nagaoka, So Takashima, Tomoya Sze-Ming, Law Yamamoto, Takuya Kurimoto, Kazuki http://hdl.handle.net/10564/4338 2024-04-30T16:30:07Z 2023-09-17T15:00:00Z タイトル: High-quality single-cell transcriptomics from ovarian histological sections during folliculogenesis 著者: Ikeda, Hiroki; Miyao, Shintaro; Nagaoka, So; Takashima, Tomoya; Sze-Ming, Law; Yamamoto, Takuya; Kurimoto, Kazuki 抄録: High-quality, straightforward single-cell RNA sequencing (RNA-seq) with spatial resolution remains challenging. Here, we developed DRaqL (direct RNA recovery and quenching for laser capture microdissection), an experimental approach for efficient cell lysis of tissue sections, directly applicable to cDNA amplification. Single-cell RNA-seq combined with DRaqL allowed transcriptomic profiling from alcohol-fixed sections with efficiency comparable with that of profiling from freshly dissociated cells, together with effective exon-exon junction profiling. The combination of DRaqL with protease treatment enabled robust and efficient single-cell transcriptome analysis from formalin-fixed tissue sections. Applying this method to mouse ovarian sections, we were able to predict the transcriptome of oocytes by their size and identified an anomaly in the size-transcriptome relationship relevant to growth retardation of oocytes, in addition to detecting oocyte-specific splice isoforms. Furthermore, we identified differentially expressed genes in granulosa cells in association with their proximity to the oocytes, suggesting distinct epigenetic regulations and cell-cycle activities governing the germ-soma relationship. Thus, DRaqL is a versatile, efficient approach for high-quality single-cell RNA-seq from tissue sections, thereby revealing histological heterogeneity in folliculogenic transcriptome. 2023-09-17T15:00:00Z http://hdl.handle.net/10564/4335 2024-04-02T16:30:09Z 2024-02-29T15:00:00Z タイトル: まほろばだより　Vol.48 2024-02-29T15:00:00Z http://hdl.handle.net/10564/4245 2024-03-08T16:30:11Z 2024-01-31T15:00:00Z タイトル: MERだより　Vol.2 2024-01-31T15:00:00Z OHARA, AYAKA SAKAKIBARA, TAKAFUMI TAKEDA, YOKO INAGAKI, ATSUSHI NOGAMI, KENJI http://hdl.handle.net/10564/4244 2024-03-07T16:30:11Z 2023-08-30T15:00:00Z タイトル: 「症例報告」OPSOCLONUS-MYOCLONUS-ATAXIA SYNDROME AFTER ADRENOCORTICOTROPIC HORMONE THERAPY FOR INFANTILE SPASMS IN A BOY WITH DOWN SYNDROME 著者: OHARA, AYAKA; SAKAKIBARA, TAKAFUMI; TAKEDA, YOKO; INAGAKI, ATSUSHI; NOGAMI, KENJI 抄録: Introduction: Opsoclonus-myoclonus-ataxia syndrome (OMAS) is a rare acquired autoimmune paraneoplastic movement disorder associated with neuroblastoma. Additionally, autoimmune diseases and infantile spasms are common comorbidities of Down syndrome (DS). Case report: A boy aged 1 year and 9 months with DS suffered from anti-seizure drug-resistant infantile spasms. We administered low-dose adrenocorticotropic hormone (ACTH; 0.0125 mg/kg/day) for 14 days, and the infantile spasms disappeared; however, he presented with limb myoclonus and involuntary conjugate multidirectional saccadic eye movements on day 3 after the end of ACTH therapy. OMAS was suspected and a complete workup was performed. No tumors, including neuroblastoma, were detected. Antibodies against glutamic acid decarboxylase 65 and Tr/Delta/Notch-like epidermal growth factor-related receptor were found. Two courses of intravenous methylprednisolone pulse therapy (30 mg/kg/day for three consecutive days), oral prednisolone (PSL) treatment (2 mg/kg/day for four consecutive days), and intravenous immunoglobulin treatment (2g/ kg/ 3days) were administered. OMAS symptoms resolved, and PSL tapering was initiated on day 17 after the start of immunomodulatory therapy. Conclusion: We present the case of a patient with DS who developed OMAS after ACTH therapy for infantile spasms. Paraneoplastic syndrome-associated antibody testing facilitated the early diagnosis of OMAS. The development of autoimmune diseases should be considered when ACTH therapy is used for DS. 2023-08-30T15:00:00Z